Company news

Vera Therapeutics, Inc. news in 2025

Vera Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

December 8, 2025

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

December 7, 2025

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

November 25, 2025

Vera Therapeutics to Participate at Upcoming Investor Conferences

November 23, 2025

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

November 9, 2025

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

November 6, 2025

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

November 5, 2025

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

November 4, 2025

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4: 30 pm ET

October 21, 2025

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

October 16, 2025

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 5, 2025

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 9, 2025

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

June 2, 2025

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

June 1, 2025

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 5, 2025

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

April 2, 2025

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

February 26, 2025

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

February 25, 2025

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

January 12, 2025

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

Decks in 2025